Recent Updates
Recently added Catalysts
SGMT

Sagimet Biosciences Reports Second Quarter 2024 Financial Results and Provides Corporate Updates

Wednesday, August 14, 2024 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Sagimet Biosciences Reports Second Quarter 2024 Financial Results and Provides Corporate Updates
Price reaction · baseline $2.66 (2024-08-13 close) · hit after-hours · clean, no other SGMT news in the window
day 0 close · peak
-7.1%
day 1
+3.8%
day 3
+6%

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+110%
120-day peak, hindsight
Typical move
5.7%
average across 12 past catalysts
Cash runway
~69 mo
Minimal dilution risk
Lead asset
TVB-2640
Phase 2 · Metabolic Dysfunction-assocated Steatohepatitis/ Nonalcoholic Fatty Liver Disease

Full Press Release Details

Sagimet Biosciences Reports Second Quarter 2024 Financial Results and Provides Corporate Updates.
ShareAdd on Google
Tags: SGMT Viatris Investor Conferences Healthcare investor conferences healthcare conferences UBS Global Healthcare
Last updated: Aug 14, 2024

Biotech snapshot

Cash runway
$258M liquidity · $4M/mo burn
~69 mo
Minimal dilution risk
Lead asset
TVB-2640Phase 2
Metabolic Dysfunction-assocated Steatohepatitis/ Nonalcoholic Fatty Liver Disease →

Catalyst track record

+110%
best trade around SGMT's most recent catalyst

Peak hindsight return over a 120-day window, across 12 tracked FDA/PDUFA catalysts for SGMT.

See every catalyst's timing & PoA →